1. Pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval Publication: [Silver Spring, MD] : United States Food and Drug Administration, Oncology Center of Excellence, July 2020 Subject(s): Breast NeoplasmsClinical Trials as TopicNeoadjuvant TherapyUnited StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.
